Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14300035 | 0.77 | HSD11B1 (0.52) | HSD11B1EPHX2MEN1KMT2ALMNA | |
| SCHEMBL13216562 | 0.74 | HSD11B1 (0.46) | HSD11B1EPHX2MEN1KMT2A | |
| SCHEMBL14570637 | 0.71 | DPP4 (0.36) | HSD11B1CTSC | |
| SCHEMBL3023692 | 0.70 | HSD11B1 (0.62) | HSD11B1EPHX2MEN1KMT2AHPGD | |
| SCHEMBL13216564 | 0.70 | HSD11B1 (0.48) | HSD11B1EPHX2MEN1KMT2A | |
| SCHEMBL7057791 | 0.69 | LMNA (0.39) | HSD11B1EPHX2MEN1KMT2ALMNA | |
| SCHEMBL13216325 | 0.68 | HSD11B1 (1.00) | HSD11B1EPHX2MEN1KMT2AHPGD | |
| SCHEMBL17356681 | 0.68 | HSD11B1 (0.58) | HSD11B1EPHX2MEN1KMT2ALMNA | |
| SCHEMBL14300039 | 0.68 | HSD11B1 (0.46) | HSD11B1EPHX2MEN1KMT2A | |
| SCHEMBL8348825 | 0.68 | CTSL (0.33) | MEN1KMT2ACTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305306-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008219-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |